This could help Bristol Myers' drug take on immunology blockbuster Dupixent, from Regeneron Pharmaceuticals ... Shares surged above their 200-day moving average for the first time since February ...

Dupixent (dupilumab) is tipped to be the market ... Sanofi says there has been more than 200 applications to receive the drug under the system, which ceases once a drug gains marketing approval.

The final appraisal document for Dupixent (dupilumab ... ILD is a diverse collection of more than 200 lung disorders, and around 13% to 40% of patients go on to develop progressive disease.